Daily Derm Times: May 8, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

AAD Partners With SOCS to Launch Inclusive Image Library

The Clinical Image Collection enhances dermatologic education by providing diverse images of skin conditions, promoting inclusivity and accurate diagnoses across all skin tones.

Evaluating Dupilumab and Upadacitinib for Head and Neck AD

New research from AAD 2025 highlights upadacitinib's effectiveness over dupilumab for treating atopic dermatitis, especially in challenging facial and neck areas.

Survey Snapshot: Chronic Hand Eczema's Clinical Burden, Treatment Gaps, and Patient Impact Revealed

We review survey data revealing diagnostic confusion, treatment gaps, and the emotional, social, and occupational toll of moderate to severe chronic hand eczema.

FDA Launches Agency-Wide AI Rollout by 2025

FDA accelerates AI integration by 2025, enhancing scientific reviews and modernizing regulatory processes for improved public health outcomes.

#DermTok: Navigating TikTok’s Acne Advice Misinformation

Social media reshapes dermatology, but misinformation about acne treatments on platforms like TikTok raises concerns among clinicians and patients alike.

Corvus Pharmaceuticals’ Soquelitinib Shows Rapid, Dose-Dependent Efficacy in Phase 1 AD Trial

Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.

Switching Gears in Atopic Dermatitis: How Upadacitinib Helps Patients Reach Optimal Targets After Dupilumab Inadequacy

Data from the Level Up study shows that switching from dupilumab to upadacitinib enables more patients to achieve optimal targets of skin clearance and itch relief.